SCHEMBL3479759

SCHEMBL3479759

CN1CCN(c2ccc3ccccc3c2)c2ccc(-n3nc4ccccn4c3=O)cc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.44
SLC6A4 P31645 4/20 0.44
SLC6A3 Q01959 4/20 0.44
HTR3A P46098 1/20 0.39
SCN9A Q15858 1/20 0.36
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
CYP17A1 P05093 1/20 0.34
HTR6 P50406 2/20 0.33
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479704 0.90 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3SCN9AALDH1A1
SCHEMBL3479670 0.88 SLC6A4 (0.45) SLC6A2SLC6A4SLC6A3SCN9AALDH1A1
SCHEMBL3479602 0.88 SLC6A4 (0.47) SLC6A2SLC6A4SLC6A3ALDH1A1GAA
SCHEMBL3480000 0.87 SLC6A4 (0.55) SLC6A2SLC6A4SLC6A3SCN9AALDH1A1
SCHEMBL3480094 0.87 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3SCN9AALDH1A1
SCHEMBL3479545 0.87 SLC6A4 (0.43) SLC6A2SLC6A4SLC6A3SCN9AALDH1A1
SCHEMBL3227717 0.86 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3HTR3ASCN9A
SCHEMBL3228837 0.85 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3SCN9AHTR1A
SCHEMBL3228568 0.79 HTR3A (0.46) SLC6A2SLC6A4SLC6A3HTR3ASCN9A
SCHEMBL3479649 0.78 HRH3 (0.47) SLC6A2SLC6A4SLC6A3HTR3ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A4 40/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.